Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-05-12
2010-12-28
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C514S168000, C514S420000, C514S494000, C514S548000, C514S665000, C514S879000, C424S641000, C424S643000
Reexamination Certificate
active
07858602
ABSTRACT:
A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include but are not limited to alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, diabetes mellitus, amyloid diseases, atherosclerosis, arthritis, osteoporosis, cystic fibrosis. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of one or more compounds that increases the presence of one or more Carbonic Anhydrase Isozymes whose levels have been reduced in the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes, a compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or a compound that when administered promotes the natural generation of the cell specific carbonic anhydrase enzymes within the subject.This method also uses one or more cells specific carbonic anhydrase as growth factors of stem cells for replacing tissues due to injuries or diseases in humans.These methods includes the administering of these compounds over an extended period of time ranging from 6 months until the subject dies.
REFERENCES:
patent: 4791099 (1988-12-01), Aroonsakul
patent: 4837219 (1989-06-01), Hutterer
patent: 4897389 (1990-01-01), Aroonsakul
patent: 5470846 (1995-11-01), Sandyk
patent: 5939407 (1999-08-01), Landfield
patent: 5972684 (1999-10-01), Bandman et al.
patent: 6013623 (2000-01-01), Spector et al.
patent: 6025395 (2000-02-01), Breitner et al.
patent: 6048553 (2000-04-01), Beckett
patent: 6150346 (2000-11-01), Knutson et al.
patent: 6262041 (2001-07-01), Serbinova
patent: 6821979 (2004-11-01), Alkon et al.
patent: 6821997 (2004-11-01), Rodriguez
patent: 6927231 (2005-08-01), Droge
patent: 6930099 (2005-08-01), Petrus
patent: 7166569 (2007-01-01), Fahy
patent: 7232809 (2007-06-01), Murphy et al.
patent: 7256184 (2007-08-01), Rodriguez
patent: 2004/0235889 (2004-11-01), Sun et al.
Gauthier et al., “Can we do better in developing new drugs for Alzheimer's disease?” Alzheimer's & Dementia, vol. 5, pp. 489-491 (2009).
Shah, R.S. et al., “Current approaches in the treatment of Alzheimer's disease,” Biomedicine & Pharmacotherapy, vol. 62, pp. 199-207 (2008).
Shah, R.M. et al., “Strategies to maximize the encapsulation efficiency of phenylalanine ammonia lyase in microcapsules,” International Journal of Pharmaceutics, vol. 356, pp. 61-68 (2008).
Abstract—“Age-dependent enzymatic changes in human cerebral cortex” by Reichlmeier, K., Aktuelle Gerontol, Aug. 1978, 8(8):441-8.
Abstract—“Neurochemical findings in the aging brain” by Meier-Ruge, et al.,Adv, Biochem Psychcopharmacol, (1980).
Abstract—“Carbonic anydrase III. Oxidative modification in vivo and loss of phosphatase activity duringAging ” by Cabiscol, et al., J. Biol. Chem. Jun. 16, 1995;270(24):14742-7.
Abstract—“Intracellular zinc depletion induces caspase activation and p21 Waf1/Dip1 cleavage in human epithelial cell lines” by Chai, et al,J Ifect DisSep. 2000:182 Suppl 1:S85-92.
Abstract—“Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency”by Henkin, et al.,Am J Med SciDec. 1999;318(6):392-405.
Abstract—“Current status of metals as therapeutic targets in Alzheimer's disease” by Finefrock, et al.,Journal of the American Geriatrics Society, (Aug. 2003) 51 (8) 1143-8.
Abstract—“Addition of carbonic anhydrase augments extracellular pH buffering in rat cerebral cortex” by Huang, et al.,J. Neurophysiol, Oct. 1995;74(4):1806-9.
Abstract—“Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action” by Puscas, et al.,Pharmacol. Exp Ther, Jun. 1996;277(3):1464-6.
Abstract—“Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression” by Aisen, et al.,JAMA The Journal of the Amercian Medical Association(2003), 289(21), 2819-2826.
Abstract—“Defective phorbol ester-stimulated secretion of .beta.-amyloid precursor protein from Alzheimer's disease fibroblasts” by Bergamaschi, et al.,Neuroscient Letters, (1995), 201(1), 1-4.
Alzheimer's Medication Fact Sheet—National Institute of Aging Retrieved from the Internet on Apr. 6, 2010.
Alzheimer's Disease—drugs slows progression of disease—Mayo Clinc Retrieved from the Internet on Apr. 4, 2010.
Smell identification test—Alzheimer's disease-Velayudhan L et a J Clin Physcopharmacol. Aug. 2009;29(4):387-90.
Acetylcholine—Wikepedia Retrieved from the Internet on Mar. 20, 2010.
Histamine—Wikedpedia Retrieved from the Internet on Mar. 24, 2010.
Phenylketonuria—Medline Plus Retrieved from the Internet on Apr. 27, 2010.
Acetylcholine synthesis and neuron differentiation- Biagoni et al-Int J Dev Biol 2000;44(6):689-97.
Testosterone no Estrogen Lackey—Protects Brain in its own right Alzheimer's Research Forum Retrieved from the Internet on Jun. 5, 2010.
LandOfFree
Therapeutic and prophylactic uses of cell specific carbonic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and prophylactic uses of cell specific carbonic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and prophylactic uses of cell specific carbonic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175970